Phase II Study of the Oral Mek Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium Trial

PURPOSE: The clinical relevance of targeting RAS/RAF/MEK/ERK pathway, activated in 70-80% of acute myeloid leukemia (AML) patients, is unknown. EXPERIMENTAL DESIGN: Selumetinib is an oral small molecule inhibitor of MEK1/2 kinase. Forty-seven patients with relapsed/refractory AML or ≥60 years old wi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Jain, Nitin, Curran, Emily, Iyengar, Neil M., Diaz-Flores, Ernesto, Kunnavakkam, Rangesh, Popplewell, Leslie, Kirschbaum, Mark H., Karrison, Theodore, Erba, Harry P., Green, Margaret, Poire, Xavier, Koval, Greg, Shannon, Kevin, Reddy, Poluru L., Joseph, Loren, Atallah, Ehab L., Dy, Philip, Thomas, Sachdev P., Smith, Scott E., Doyle, L. Austin, Stadler, Walter M., Larson, Richard A., Stock, Wendy, Odenike, Olatoyosi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4310865/
https://ncbi.nlm.nih.gov/pubmed/24178622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1311
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak